Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Abstract Background Radiotherapy may work synergistically with immunotherapy and targeted agents. We aimed to assess the safety and outcomes of stereotactic body radiotherapy (SBRT) plus non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) in metastatic renal cell carcinoma (...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Liu, Zhiling Zhang, Ruiqi Liu, Wensu Wei, Zitong Zhang, Lixin Mai, Shengjie Guo, Hui Han, Fangjian Zhou, Liru He, Pei Dong
Format: article
Language:EN
Published: BMC 2021
Subjects:
Renal cell carcinoma
Metastasis
Anti-PD-1 therapy
Targeted therapy
Stereotactic body radiation therapy
Medical physics. Medical radiology. Nuclear medicine
R895-920
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/3e0f90f743e142d0bc4168cf48440244
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/3e0f90f743e142d0bc4168cf48440244

Similar Items